SUPRIYA LIFESCIENCE Financial Statement Analysis
|
||
|
The Revenues of SUPRIYA LIFESCIENCE have increased by 22.12% YoY .
The Earnings Per Share (EPS) of SUPRIYA LIFESCIENCE has increased by 57.77 % YoY. |
||
SUPRIYA LIFESCIENCE Last 5 Annual Financial Results
[BOM: 543434|NSE : SUPRIYA]
| Standalone | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹696 Cr | ₹570 Cr | ₹461 Cr | ₹530 Cr | ₹391 Cr |
| Expenses | ₹436 Cr | ₹395 Cr | ₹332 Cr | ₹316 Cr | ₹218 Cr |
| Operating Profit (Excl OI) | ₹261 Cr | ₹176 Cr | ₹128 Cr | ₹214 Cr | ₹173 Cr |
| Other Income | ₹9.82 Cr | ₹11 Cr | ₹9.94 Cr | ₹7.58 Cr | ₹5.01 Cr |
| Interest | ₹1.83 Cr | ₹5.15 Cr | ₹3.08 Cr | ₹4.20 Cr | ₹4.08 Cr |
| Depreciation | ₹20 Cr | ₹16 Cr | ₹12 Cr | ₹10 Cr | ₹6.76 Cr |
| Profit Before Tax | ₹248 Cr | ₹166 Cr | ₹123 Cr | ₹207 Cr | ₹167 Cr |
| Profit After Tax | ₹188 Cr | ₹119 Cr | ₹90 Cr | ₹152 Cr | ₹124 Cr |
| Earnings Per Share (Rs) | ₹23.35 | ₹14.80 | ₹11.16 | ₹18.86 | ₹16.89 |
| PAT Margin (%) | 24.04 | 18.41 | 17.40 | 25.80 | 28.68 |
| ROE(%) | 20.74 | 15.73 | 13.66 | 34.34 | 59.17 |
| ROCE(%) | 27.63 | 22.31 | 18.71 | 43.34 | 60.12 |
| Total Debt/Equity(x) | 0.00 | 0.00 | 0.02 | 0.03 | 0.26 |
Key Financials |
||
| Market Cap | : | ₹ 5,550.1 Cr |
| Revenue (TTM) | : | ₹ 735.5 Cr |
| Net Profit(TTM) | : | ₹ 185.3 Cr |
| EPS (TTM) | : | ₹ 23.0 |
| P/E (TTM) | : | 30.0 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| SUPRIYA LIFESCIENCE | -3.9% | 8.2% | 3.3% |
| SUN PHARMACEUTICAL INDUSTRIES | 0.4% | 10.8% | 10.5% |
| DIVIS LABORATORIES | 0.7% | 9.5% | 16.5% |
| CIPLA | 9.7% | 16.7% | -4.9% |
| TORRENT PHARMACEUTICALS | -2.5% | 6% | 36.2% |
| DR REDDYS LABORATORIES | 4.5% | 9.7% | 9% |
| MANKIND PHARMA | 1.4% | 18% | -1.4% |
| ZYDUS LIFESCIENCES | 5.7% | 8% | 12.1% |
| LUPIN | 1.3% | -2.8% | 10.6% |
SUPRIYA LIFESCIENCE Revenues
[BOM: 543434|NSE : SUPRIYA]
| Y-o-Y | 22.12 % |
| 5 Yr CAGR | 15.51 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹696 Cr | 22.12 | |
| Mar2024 | ₹570 Cr | 23.73 | |
| Mar2023 | ₹461 Cr | -13.04 | |
| Mar2022 | ₹530 Cr | 35.49 | |
| Mar2021 | ₹391 Cr | - | |
SUPRIYA LIFESCIENCE Operating Profit
[BOM: 543434|NSE : SUPRIYA]
| Y-o-Y | 48.51 % |
| 5 Yr CAGR | 10.80 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹261 Cr | 48.51 | |
| Mar2024 | ₹176 Cr | 36.79 | |
| Mar2023 | ₹128 Cr | -39.98 | |
| Mar2022 | ₹214 Cr | 23.59 | |
| Mar2021 | ₹173 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 21.58 % |
| 5 Yr CAGR | -4.08 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 37.46% | 21.58 | |
| Mar2024 | 30.81% | 10.55 | |
| Mar2023 | 27.87% | -30.96 | |
| Mar2022 | 40.37% | -8.79 | |
| Mar2021 | 44.26% | - | |
SUPRIYA LIFESCIENCE Profit After Tax
[BOM: 543434|NSE : SUPRIYA]
| Y-o-Y | 57.80 % |
| 5 Yr CAGR | 11.05 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹188 Cr | 57.80 | |
| Mar2024 | ₹119 Cr | 32.56 | |
| Mar2023 | ₹90 Cr | -40.81 | |
| Mar2022 | ₹152 Cr | 22.83 | |
| Mar2021 | ₹124 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 30.58 % |
| 5 Yr CAGR | -4.32 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 24.04 % | 30.58 | |
| Mar2024 | 18.41 % | 5.80 | |
| Mar2023 | 17.4 % | -32.56 | |
| Mar2022 | 25.8 % | -10.04 | |
| Mar2021 | 28.68 % | - | |
SUPRIYA LIFESCIENCE Earnings Per Share (EPS)
[BOM: 543434|NSE : SUPRIYA]
| Y-o-Y | 57.77 % |
| 5 Yr CAGR | 8.43 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹23 | 57.77 | |
| Mar2024 | ₹15 | 32.62 | |
| Mar2023 | ₹11 | -40.83 | |
| Mar2022 | ₹19 | 11.66 | |
| Mar2021 | ₹17 | - | |
SUPRIYA LIFESCIENCE Return on Capital Employed (ROCE)
[BOM: 543434|NSE : SUPRIYA]
| Y-o-Y | 23.85 % |
| 5 Yr CAGR | -17.66 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 27.63% | 23.85 | |
| Mar2024 | 22.31% | 19.24 | |
| Mar2023 | 18.71% | -56.83 | |
| Mar2022 | 43.34% | -27.91 | |
| Mar2021 | 60.12% | - | |
SUPRIYA LIFESCIENCE Share Price vs Sensex
| Current Share Price | : | ₹689.5 |
| Current MarketCap | : | ₹ 5,550.1 Cr |
| Updated EOD on | : | May 15,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SUPRIYA LIFESCIENCE | -3.9% |
8.2% |
3.3% |
| SENSEX | -2.7% |
-2.1% |
-5.3% |
SUPRIYA LIFESCIENCE related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE HEALTHCARE | 1.4% | 11% | 14.5% |
| BSE SMALLCAP | -5.8% | -8.9% | -10.5% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY TOTAL MARKET | -2.6% | 1.8% | 4.2% |
| NIFTY MICROCAP 250 | -3.9% | 7.6% | 11.2% |
You may also like the below Video Courses
FAQ about SUPRIYA LIFESCIENCE Financials
How the annual revenues of SUPRIYA LIFESCIENCE have changed ?
The Revenues of SUPRIYA LIFESCIENCE have increased by 22.12% YoY .
How the Earnings per Share (EPS) of SUPRIYA LIFESCIENCE have changed?
The Earnings Per Share (EPS) of SUPRIYA LIFESCIENCE has increased by 57.77 % YoY .
Check out Intrinsic Value of Peers of SUPRIYA LIFESCIENCE
Compare Stock Analytics of Peers of SUPRIYA LIFESCIENCE
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
